Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acelyrin Inc (NQ: SLRN )

6.760 +0.050 (+0.75%)
Streaming Delayed Price Updated: 3:37 PM EDT, Jul 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acelyrin Inc

< Previous 1 2 3 4 5 6 Next >
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
From ACELYRIN, INC.
Via GlobeNewswire
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is Investigating Acelyrin, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Leadership Transition
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
From ACELYRIN, INC.
Via GlobeNewswire
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
From Avalo Therapeutics
Via GlobeNewswire
Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients
Acelyrin releases Phase 1/2 trial results of lonigutamab. Rapid improvements in eye bulge and double vision. Well-tolerated with no serious adverse events. Phase 2b/3 trial slated for the second half... 
Via Benzinga
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
From ACELYRIN, INC.
Via GlobeNewswire
Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study
Acelyrin reports positive Phase 2b/3 trial results for izokibep in psoriatic arthritis, achieving ACR50 at week 16 with high statistical significance. Long-term data in hidradenitis suppurativa show... 
Via Benzinga
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
From ACELYRIN, INC.
Via GlobeNewswire
Acelyrin (SLRN) Investor Update: Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SLRN DEADLINE TOMORROW: ROSEN, A LEADING NATIONAL FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
WHY: NEW YORK, NY - (NewMediaWire) - January 15, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and... 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SLRN DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
WHY: NEW YORK, NY - (NewMediaWire) - January 14, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and... 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SLRN DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ACELYRIN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Acelyrin, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SLRN IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action SLRN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SLRN DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors with Losses in Excess of $100k to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Acelyrin, and Beauty Health and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SLRN IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important January 16 Deadline in Securities Class Action - SLRN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options
From Faruqi & Faruqi LLP
Via GlobeNewswire
Final Deadline Approaching for SLRN Investors: Kessler Topaz Meltzer & Check, LLP Reminds Acelyrin, Inc. (SLRN) Investors of Class Action Lawsuit Deadline on January 16, 2024
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important January 16 Deadline in Securities Class Action – SLRN
From The Rosen Law Firm PA
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.